Introduction
At the end of 2007 there were approximately 33 million people living with HIV worldwide (UNAIDS, 2008) . Across the globe HIV comprises a variety of major groups and subtypes, however, group M overwhelmingly predominates, and within this group subtypes B, C and A/E recombinants are the most prevalent subtypes. Viruses of a specific subtype are genetically more related to one another and often cluster in geographic regions because of founder effects. Whether subtypes differ from one another in their propensity to cause neurologic disease remains unclear. But the majority of research on HIV CNS disease has taken place in regions where subtype B is prevalent.
Systemic pathogenesis
Human immunodeficiency virus type 1 (HIV-1) principally infects activated CD4+ lymphocytes, and secondarily infects cells of the monocyte-macrophage lineage, which then carry virus into the CNS. Acute infection may go unnoticed, as symptoms are quite nonspecific. What was once considered to be a period of clinical latency lasting many years after acute infection is now recognized as a time of continuous high level viral replication and immune activation that leads to gradual depletion of CD4+ lymphocytes. The HIV pandemic represents a major source of neurological morbidity worldwide. Emerging data from diverse populations indicate that HIV leads to significant neurocognitive impairments that reduce individuals' ability to contribute to the well being of their families and society. HIV affects vulnerable populations with many comorbidities, but the virus contributes to neurocognitive impairment independent of these conditions. The neuropathological substrate of HIV neurocognitive disorders is damage to synapses and dendrites, without major neuronal loss. This suggests the potential for substantial reversibility if synaptodendritic function can be restored. In the developed world, combination antiretroviral therapy (CART) leads to improved neurocognitive function as well as morbidity and mortality in HIV. CART is being used in increasing numbers of individuals in resource limited settings. New cases of severe dementia are now rare in populations where effective CART has been deployed. While some degree of neurocognitive improvement with CART is almost universal, many individuals do not achieve full restoration of their premorbid neurocognitive status, and milder degrees of impairment remain quite prevalent. Optimizing neurocognitive recovery is likely to require the development of better CNS penetrating antiretroviral regimens and the use of neuroprotective agents.
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